NCT07197645招募中1 期
A Phase 1 Pharmacokinetic, Dosimetry, Safety, and Dose Optimization Study for a Single Dose of TLX090-Tx (153SmDOTMP) to Treat Metastatic Bone Pain
Telix Pharmaceuticals (Innovations) Pty Limited6 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2025年10月21日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 33
- 试验地点
- 6
- 主要终点
- Incidence and severity of treatment-emergent adverse events (TEAEs) [Safety and Tolerability]
研究概览
简要总结
This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants have had disease progression while on anti-cancer treatment, and are not eligible for the treatments, or their lesions are not amenable to palliative EBRT.
- •Participants must have a histologically confirmed diagnosis of malignancy at any time prior to their participation in this clinical trial with multiple metastatic bone lesions with at least 1 metastatic painful osteoblastic tumor that causes a minimum pain score of 4 on the NRS
- •Participants must have bone cancer in one or more skeletal locations as identified by a 99mTc-diphosphonate bone scan within 60 days of dosing. At least one lesion must be osteoblastic. If described as osteosclerotic, radiology confirmation that the lesion is osteoblastic is required. Adequate organ function, including:
- •Renal function, defined as a measured creatinine clearance (CrCl) ≥30 mL/min as per Cockroft Gault or based on radioisotope glomerular filtration rate (GFR).
- •Hematologic function, defined as a platelet count of >100,000 cells/mm3 and an Absolute neutrophil count (ANC) of >1000 cells/mm
- •Hemoglobin ≥8 g/dL.
- •Liver function:
- •Total bilirubin ≤1.5 × the upper limit of normal (ULN).
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5 × ULN with participants with known liver metastases.
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3 × ULN with participants with Gilbert's Syndrome.
- •Life expectancy of at least 16 weeks from the date of study drug administration (Day 1).
- •Karnofsky performance status >60%, assessed during the screening period prior to study drug administration.
排除标准
- •Participants are pregnant or breastfeeding.
- •Participants who have received maximum tolerable radiation to the spinal cord, have untreated pathologic bone fracture, spinal cord compression, unstable spine, or imminent long bone fracture.
- •Participants with a bone scan pattern showing diffuse, intense skeletal uptake with absent or faint kidney / bladder activity, typically indicating widespread bone metastases or high bone turnover from metabolic or hematologic diseases (Superscan) pattern on Technetium 99-m bone scan scintigraphy - defined as diffusely increased skeletal uptake with absent or markedly reduced renal and soft tissue visualization - are excluded from the study.
- •Participants with impending or suspected or at high risk for spinal cord compression.
- •Participants with neurogenic pain or significant pain associated with soft tissue lesions or other pain that, in the opinion of the Investigator, might interfere with the assessment of pain relief for bone tumors.
- •Participants who require surgery over their trial period that would require pain medication or analgesia.
- •Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product.
- •History of unstable angina (defined as angina at rest) or new-onset angina diagnosed within the 3 months prior to screening.
- •History of myocardial infarction within 3 months prior to screening, as determined by medical history / Baseline ECG.
- •Uncontrolled cardiac arrhythmias (≥Grade 3 CTCAE version 5.0) or any history of ≥Grade 3 arrhythmia.
- •Congestive heart failure ≥New York Heart Association Class
- •Clinically significant abnormalities on ECG at screening including corrected QT interval (Fridericia's formula) >450 msec for males or 470 msec for females at screening.
- •Inability to complete the needed investigational and standard imaging examinations due to any reason (eg, severe claustrophobia, inability to lie still for the entire imaging time).
- •Presence of any other condition that may increase the risk associated with study participation or interfere with the interpretation of study results, and, in the opinion of the study Investigator, would make the participant inappropriate for entry into the study.
- •Participants with active infections (human immunodeficiency virus, human papillomavirus. Hepatitis A, Hepatitis B, and Hepatitis C).
研究组 & 干预措施
Part A - Cohort 1
Experimental
Dose Escalation
干预措施: 153Sm-DOTMP (Drug)
结局指标
主要结局
Incidence and severity of treatment-emergent adverse events (TEAEs) [Safety and Tolerability]
时间窗: Up to 6 weeks post-dose
Incidence and severity of hematologic and non-hematologic toxicities, graded per CTCAE v5.0, assessed through 6 weeks post-dose.
次要结局
- Change from baseline in patient-reported bone pain severity using the NRS-11 scale on the form(Baseline to 16 weeks post-dose)
研究者
研究点 (6)
Loading locations...
相似试验
终止
1 期
A Study of TAS1440 With ATRA in Subjects With r/r AMLAcute Myeloid LeukemiaNCT04282668Taiho Oncology, Inc.52
已完成
1 期
A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.Solid TumorsNCT04341259Hoffmann-La Roche12
已完成
1 期
Evaluate the Safety and Pharmacokinetics of RicolinostatPeripheral Nervous System DiseasesNCT05193851Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.12
已完成
1 期
A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid TumorsAdvanced Solid Tumors CancerNCT03311477AbbVie9
已完成
1 期
Phase I Study of U3P1287/01, Including Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT00730470U3 Pharma GmbH60